FibroScan® Probes
Fit the patient morphology with the appropriated probe
The portable non-invasive solution for efficient liver disease management
Powered by LSM by VCTE™ and CAP™* for liver fibrosis and liver steatosis assessment.
With its optional roll stand, 15” interactive touchscreen display and durable ergonomic design, FibroScan® Compact 530 is the perfect liver assessment solution for any point-of-care setting.
LSM by VCTE™ is unique, patented and validated for liver fibrosis assessment. It is the standard for non-invasive evaluation of liver stiffness1 with 3,800 international peer-reviewed publications.
CAP™ is unique patented and validated for liver steatosis assessment2,3 with 1,130 international peer-reviewed publications.
*CAP™ is available as an option.
Products in the FibroScan® range are Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459). These devices are designed for use in a medical practice in order to measure liver stiffness and ultrasound attenuation in patients with liver disease. Examinations with FibroScan® device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies.
Bibliography
1.European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.
2.Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi:10.1016/j.jhep.2016.12.022.
3.Recio E, Cifuentes C, Macías J, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool or the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol. 2013;25(8):905-911.doi:10.1097/MEG.0b013e32835f4c3d.
Fit the patient morphology with the appropriated probe
Enhance your FibroScan® capabilities for improved management of fatty liver patients
Optimize clinical workflows with real-time secure data transmission
Enhance FibroScan® liver disease assessment with biological markers